Navigation Links
Adult Sickle Cell Drug May Benefit Kids, Too
Date:12/12/2011

By Serena Gordon
HealthDay Reporter

SUNDAY, Dec. 11 (HealthDay News) -- A drug called hydroxyurea that's approved for use in adults with severe sickle cell anemia can also help young children with the disease, new research suggests.

Children with sickle cell anemia younger than 4 years old who took the medication had fewer emergency department visits for pain crises, hospital admissions, illnesses with fever and need for transfusions, the study found.

"Hydroxyurea may be an option for all children with sickle cell anemia. If you're the parent of a child with sickle cell anemia, talk with your child's doctor about whether it might be right for your child," said study lead author Dr. Zora Rogers, a professor of pediatrics at the University of Texas Southwestern Medical Center, Dallas.

"We don't see a difference in toxicity; we don't see a big difference in growth," said Rogers, who's also clinical director of the bone marrow failure and general hematology program at Children's Medical Center in Dallas. "Hydroxyurea is not causing any obvious harm. We'll need to follow the children through adolescence, but right now the oldest is 9."

Rogers was scheduled to present the study's findings Sunday at the annual meeting of the American Society of Hematology in San Diego.

In sickle cell anemia, red blood cells become rigid and develop a crescent, or sickle, shape, often leading to pain, infection, organ damage, and even stroke. Hydroxyurea makes it less likely that red blood cells will bend abnormally, according to the U.S. National Institutes of Health. People taking the drug must get monthly blood counts to verify they're on the most effective dose, Rogers said.

The new study followed up on one done with babies and toddlers with sickle cell anemia. In that earlier study, nearly 200 babies between 9 and 18 months old were randomly selected to receive treatment with either hydroxyurea or a placebo. The study, called Baby Hug, found that children on hydroxyurea had fewer pain crises, acute chest syndrome events, blood transfusions and hospital admissions.

Parents of the 176 children who completed at least 18 months of the Baby Hug study were offered a chance to participate in the current follow-up study, sponsored by the U.S. National Heart, Lung, and Blood Institute. One hundred and sixty-three children continued in the study.

All the children had the chance to take hydroxyurea in the follow-up study. One hundred and thirty three parents chose the drug.

Researchers have seen each child every six months, and now have 36 months of follow-up data. Rogers said the researchers have almost 500 patient-years of follow-up information.

As with the initial study, the follow-up study saw fewer ER visits for pain crises, transfusions and hospital admissions. For each 100 patient-years, the study found 28.8 emergency room visits for pain crises for those children on hydroxyurea, compared to 53.6 for those on a placebo. For transfusions, there were 18.3 per 100 patient-years for kids on the medication, versus 35.9 for those on a placebo. There were 72.9 hospital admissions per 100 patient-years for those receiving treatment, and 131.7 for those taking a placebo.

The follow-up also found fewer illnesses with fever -- 28.5 per 100 patient years for kids on the drug and 61.5 for children not taking the drug.

"The benefits outweigh the risks for hydroxyurea when administered under supervision," said Dr. Lakshmanan Krishnamurti, director of hematology and hemoglobinopathy at Children's Hospital of Pittsburgh. "This study [offers] a ray of hope and shows us a way to move forward. I hope it leads to change in how physicians think about patients with sickle cell disease. Families can undertake medications and they will come for monitoring."

"We know what 30 years of sickle cell does to a body," Krishnamurti added. "This study shifts the paradigm from chronic palliation to an attempt to give the medication that now has a demonstrated track record of efficacy before damage is done."

A second study, also to be presented Sunday at the meeting, looked at the potential for a side effect from hydroxyurea called genotoxicity. A drug with genotoxic effects has the potential to damage DNA. Some laboratory tests had suggested that this could be possible with hydroxyurea.

Researchers from the Baylor College of Medicine in Houston and elsewhere looked for evidence of DNA damage in the babies and toddlers enrolled in the Baby Hug study. They found no significant differences in signs indicating DNA damage between kids on the drug and kids on a placebo, suggesting that any potential for genotoxicity is low.

Research presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

More information

To learn more about hydroxyurea, visit the U.S. National Library of Medicine.

SOURCES: Zora Rogers, M.D., professor of pediatrics, University of Texas Southwestern Medical Center at Dallas, and clinical director, bone marrow failure and general hematology program, Children's Medical Center in Dallas; Lakshmanan Krishnamurti, M.D., director, hematology and hemoglobinopathy, Children's Hospital of Pittsburgh, and associate professor of pediatrics, University of Pittsburgh School of Medicine; Dec. 11, 2011, presentations, American Society of Hematology annual meeting, San Diego


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Taxi Drivers Show How Learning Changes Adult Brain
2. Very Low Birth Weight May Affect Adult Memory, IQ
3. Prozac Might Ease Repetitive Behaviors in Some Adults With Autism
4. Health gap has grown among young US adults, study finds
5. Hypertension in Young Adulthood May Mean Trouble Later On
6. Older adults in home health care at elevated risk for unsafe meds
7. New report highlights LGBT older adults needs, identifies policy opportunities
8. Smart Kids More Likely to Try Illicit Drugs as Young Adults
9. Childhood Aggression May Predict Health Woes in Adulthood
10. Abused girls may have higher risk of heart disease, stroke as adults
11. Abused Girls at Greater Risk for Heart Disease as Adults: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Adult Sickle Cell Drug May Benefit Kids, Too
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with ... that works for them. When an inventor from Suisun City, Calif., was unsuccessful in ... share it with others. , He developed a prototype for PRO GO MASSAGE to ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology: